In a patient with complex PTSD, autism, and 8 months of protracted withdrawal syndrome who cannot take GABAergic medications, would starting Auvelity (dextromethorphan‑bupropion), low‑dose doxepin for sleep, and bioidentical hormone replacement therapy (transdermal estradiol patch plus oral micronized progesterone) be appropriate and helpful?

Recommendation for Auvelity, Doxepin, and HRT in CPTSD, Autism, and PAWS

I cannot recommend Auvelity (dextromethorphan-bupropion) for your situation because you have complex PTSD and autism, and the FDA labeling specifically warns about increased risk of manic episodes, unusual thoughts/behaviors, and neuropsychiatric reactions—risks that are amplified in neurodivergent individuals with trauma histories. 1

Why Auvelity Is Problematic for Your Case

Contraindications and High-Risk Factors

The FDA labeling for Auvelity explicitly warns about:

• Manic episodes and unusual thoughts/behaviors - particularly concerning given your CPTSD and autism, where emotional dysregulation and sensory processing differences already exist 1
• Increased neuropsychiatric reactions - the bupropion component can cause agitation, anxiety, panic attacks, and acting on dangerous impulses 1
• Seizure risk - elevated in individuals with history of head injury, and autism itself may carry higher seizure susceptibility 1

Evidence Conflicts With Your Presentation

While one small case series suggested bupropion might help PTSD with comorbid methamphetamine use disorder 2, this is not applicable to your situation—you have CPTSD (more complex than PTSD) and PAWS from protracted withdrawal, not active substance use disorder. The 2024 VA/DoD PTSD guidelines do not recommend bupropion for PTSD treatment, instead strongly recommending specific trauma-focused psychotherapies and serotonergic agents (paroxetine, sertraline, venlafaxine) 3.

The autism treatment guidelines from 2025 do mention bupropion as a third-line option for depression in autism—but only after duloxetine, mirtazapine, and vortioxetine have been tried, and notably not for PTSD or withdrawal syndromes 4.

The PAWS Complication

Your 8-month protracted withdrawal syndrome is a critical factor. Research shows PAWS can last 5-166 months (median 26 months) and presents with:

• Affective symptoms (anxiety, depression, emerging suicidality, agitation) in 81%
• Somatic symptoms (headache, fatigue, dizziness, brain zaps) in 75%
• Sleep problems in 44%
• Cognitive impairments in 32% 5

Adding Auvelity during active PAWS is particularly risky because:

1. The bupropion component can worsen anxiety, agitation, and emerging suicidality—symptoms already present in 81% of PAWS cases 5
2. You cannot take GABAergic medications, eliminating your safety net if Auvelity triggers severe anxiety or agitation
3. The stimulant-like properties of bupropion may destabilize your already fragile neurochemistry during withdrawal 1

Doxepin for Sleep: Reasonable Option

Low-dose doxepin (3-6 mg) for sleep is appropriate and relatively safe in your situation. At these doses, it acts primarily as an H1-antihistamine with minimal anticholinergic effects, making it suitable for insomnia without GABAergic mechanisms. This addresses the 44% prevalence of sleep problems in PAWS 5.

Bioidentical HRT: Potentially Helpful But Timing Matters

Transdermal estradiol and oral micronized progesterone may provide modest benefit for mood and sleep, particularly if you're perimenopausal or postmenopausal. However:

• Estrogen can modulate glutamate and dopamine systems, which may help with your stated goals
• Progesterone has GABAergic metabolites (allopregnanolone), which could theoretically help sleep—but you stated you cannot take GABAergic medications, so monitor for paradoxical reactions
• Start HRT only after your PAWS symptoms have stabilized (typically after 12+ months), as adding multiple neurochemical changes simultaneously makes it impossible to identify what's helping versus harming

What You Should Do Instead

Immediate Priorities (Months 8-12 of PAWS)

1. Continue supportive care through PAWS recovery - most cases show improvement by 26 months median 5
2. Start low-dose doxepin (3-6 mg) for sleep only
3. Avoid Auvelity entirely - the risks far outweigh theoretical benefits in your complex presentation
4. Engage in trauma-focused psychotherapy - prolonged exposure, cognitive processing therapy, or EMDR are strongly recommended for CPTSD 3

After PAWS Stabilization (Month 12+)

If depression persists after PAWS resolves:

1. First-line for depression in autism: Try duloxetine, mirtazapine, or vortioxetine—NOT SSRIs or bupropion initially 4
2. For CPTSD: Consider paroxetine, sertraline, or venlafaxine per VA/DoD guidelines 3
3. Consider HRT at this point if perimenopausal/postmenopausal symptoms are present

Critical Pitfall to Avoid

Do not layer multiple psychoactive medications during active PAWS. The research shows PAWS involves "multiple body system impairments" with heterogeneous symptoms 5. Adding Auvelity's complex pharmacology (NMDA antagonism, dopamine-norepinephrine reuptake inhibition, sigma-1 receptor activity) during this vulnerable period creates unpredictable interactions with your recovering neurochemistry.

Your inability to use GABAergic rescue medications makes this even more dangerous—if Auvelity triggers severe anxiety, agitation, or emerging suicidality (all listed as serious adverse effects 1), you have no pharmacological safety net.